BD Biosciences Antibodies

expired opportunity(Expired)
From: Federal Government(Federal)
RFQ-NIAID-2028850

Basic Details

started - 01 Jul, 2020 (about 3 years ago)

Start Date

01 Jul, 2020 (about 3 years ago)
due - 06 Jul, 2020 (about 3 years ago)

Due Date

06 Jul, 2020 (about 3 years ago)
Bid Notification

Type

Bid Notification
RFQ-NIAID-2028850

Identifier

RFQ-NIAID-2028850
HEALTH AND HUMAN SERVICES, DEPARTMENT OF

Customer / Agency

HEALTH AND HUMAN SERVICES, DEPARTMENT OF (26896)NATIONAL INSTITUTES OF HEALTH (10881)NATIONAL INSTITUTES OF HEALTH NIAID (1807)

Attachments (4)

unlockUnlock the best of InstantMarkets.

Please Sign In to see more out of InstantMarkets such as history, intelligent business alerts and many more.

Don't have an account yet? Create a free account now.

This notice is a combined synopsis/solicitation for commercial items using Simplified Acquisition Procedures. This acquisition will be made in accordance with the format in Federal Acquisition Regulation (FAR) Subpart 12.6 “Streamlined Procedures for Evaluation and solicitation for commercial Items,” as applicable, and as supplemented with additional information included in this notice. This announcement constitutes the only solicitation (a written solicitation will not be issued) and quotes are being requested. The Solicitation number is RFQ-NIAID-2028850 and the solicitation is issued as a Request for Quotes (RFQ).This acquisition will be processed under FAR Part 13 Simplified Acquisition Procedures (SAP). The solicitation documents and incorporated provisions and clauses are those in effect through Federal Acquisition Circular (FAC) 2020-06, Effective 06/05/2020. The North American Industry Classification System (NAICS) code for this procurement is 325413, In-Vitro Diagnostic
Substance Manufacturing, with a small business size standard of 1250 employees.This requirement is NOT set-aside for small business.Background: The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease (COVID-19) in China at the end of 2019 has now caused a major global pandemic threatening large swaths of the human population. There is an urgent need for a stabilizing formulation buffer used in vaccine development and production.SARS-CoV-2 is a newly discovered coronavirus that has caused the global pandemic, COVID-19, resulting in hundreds of thousands of deaths since January 2020. In order to rapidly bring candidate vaccines to the public and put a stop to widespread illness and death, multiple vaccine candidates are undergoing parallel development at unprecedented speed.The Helminth Immunology Section requires specific antibodies to continue research on potential vaccine candidate for COVID-19.Please see attachment for list of BD Biosciences antibodies.Place of Performance: Leidos Biomedical Research, 1050 Boyles St, Frederick, MD 21702Delivery date: 30 weeks ARO*Please include your DUNS number on quote*Include response to FAR 52.204-26 attachment and return with quote*Include response to FAR 52.204-24 if applicableSubmission shall be received not later than 9 a.m. EST, July 6, 2020.The government intends to award a firm fixed price purchase order to the responsible contractor as a result of this RFQ that will include the terms and conditions set forth herein.  The award will be based on the following; price, capability to meet the requirements, delivery and the best value to the government.The following FAR provisions apply to this acquisition:FAR 52.204-24 Representation Regarding Certain Telecommunications and Video Surveillance Services or Equipment (Dec 2019)FAR 52.204-26 Covered Telecommunications Equipment or Services-Representation (Dec 2019)FAR 52.212-1 Instructions to Offerors Commercial Items (Jun 2020)FAR 52.212-3 Offerors Representations and Certifications - Commercial Items (Jun 2020)Offerors must complete annual representations and certifications on-line at http://www.sam.gov/ in accordance with FAR 52.212-3 Offerors Representations and Certifications- Commercial Items (Please ensure 52.209-2 -- Prohibition on Contracting with Inverted Domestic Corporations--Representation. (Nov 2015) is updated in your SAM record)FAR 52.203-18 Prohibition on Contracting with Entities that Require Certain Internal Confidentiality Agreements – Representation (Jan 2017)The following FAR contract clauses apply to this acquisition:FAR 52-212-4 Contract Terms and Conditions Commercial Items (Oct 2018)FAR 52-212-5 Contract Terms and Conditions Required to Implement Statutes or Executive Orders Commercial Items (Jun 2020)*The applicable subparagraphs of FAR52.212-5 are included in the attachment to this posting.FAR 52.203-19 Prohibition on Contracting with Entities that Require Certain Internal Confidentiality Agreements (Jan 2017)FAR 52.204-25 Prohibition on Contracting for Certain Telecommunications and Video Surveillance Services or Equipment (Aug 2019)FAR 52.232-40 Providing Accelerated Payments to Small Business Subcontractors (Dec 2013)FAR 52.204-19 Incorporation by Reference of Representations and Certifications (Dec 2014)HHSAR 352.222-70, Contractor Cooperation in Equal Employment Opportunity Investigations (Dec 2015)By submission of an offer, the offeror acknowledges the requirement that a prospective awardee shall be registered in the System for Award Management (SAM) database prior to award, during performance, and through final payment of any contract, basic agreement, basic ordering agreement, or blanket purchasing agreement resulting from this solicitation (www.sam.gov).Copies of the above-referenced provisions and clauses are available from http://www.acquisition.gov & http: //www.hhs.gov/regulation/index.html or, upon request, either by telephone or fax.Offers may be mailed, e-mailed or faxed to Ms. Skye Duffner, (E-Mail/ skye.duffner@nih.gov 406-802-6092). Late submissions shall be treated in accordance with the solicitation provision at FAR 52.212-1(f) (Oct 2018)All responsible sources may submit an offer that will be considered by this Agency. Any questions or concerns regarding this solicitation should be forwarded in writing via e-mail to Ms. Skye Duffner at skye.duffner@nih.gov.

Frederick ,
 MD  21702  USALocation

Place Of Performance : N/A

Country : United StatesState : MarylandCity : Frederick

You may also like

Notice of Intent to Sole Source Element Biosciences Aviti System

Due: 26 Apr, 2024 (Tomorrow)Agency: HEALTH AND HUMAN SERVICES, DEPARTMENT OF

MAINTENANCE/SERVICE AGREEMENT FOR BD BIOSCIENCES FACSLYRIC EQUIPMENT

Due: 31 Jan, 2028 (in about 3 years)Agency: NATIONAL INSTITUTES OF HEALTH

MAINTENANCE CONTRACT FOR THE BD FORTESSA FLOW CYTOMETER ANALYZER

Due: 12 Jan, 2025 (in 8 months)Agency: NATIONAL INSTITUTES OF HEALTH

Please Sign In to see more like these.

Don't have an account yet? Create a free account now.

Classification

naicsCode 325413In-Vitro Diagnostic Substance Manufacturing
pscCode 6505Drugs and Biologicals